Immunoglobulin fusion proteins

• US 7,867,491 B2
• Filed: 05/30/2008
• Issued: 01/11/2011
• Est. Priority Date: 05/30/2007
• Status: Active Grant

• Current Assignee: Genexine, Inc., Postech Academy-Industry Foundation Pohang University Of Science & Technology
• Original Assignee: Genexine Co., Ltd., Postech Academy-Industry Foundation Pohang University Of Science & Technology
• Inventors: Yang, Sehwan, Sung, Young Chul
• Primary Examiner(s): Spector; Lorraine
• Assistant Examiner(s): STOICA, ELLY GERALD
• Application Number:
  US12/130,002
• Publication Number:
  US 20080300188A1
• Time in Patent Office: 956 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/06 of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/53 Hinge
• CPC Class Codes: C07K 2317/60 characterized by non-natural combinations of immunoglobulin fragments
• CPC Class Codes: C07K 2319/30 : Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/62 : DNA sequences coding for fusion proteins

Abstract

Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.

Claims

1. A polypeptide represented by the following formula:

N′

—

(Z1)_p—

Y—

Z2—

Z3—

Z4—

C′

wherein N′

is the N-terminus and C′

is the C-terminus of the polypeptide,

Z1 is an amino acid sequence consisting of the amino acid residues at positions 90 to 98 of SEQ ID NO;

14;

Y is an amino acid sequence consisting of 5 or more consecutive amino acid residues from the C-terminus at positions 99 to 162 of SEQ ID NO;

14;

Z2 is an amino acid sequence consisting of the amino acid residues at positions 163 to 170 of SEQ ID NO;

14;

Z3 is an amino acid sequence consisting of the amino acid residues at positions 121 to 220 of SEQ ID NO;

13;

Z4 is an amino acid sequence consisting of the amino acid residues at positions 221 to 327 of SEQ ID NO;

13; and

p is an integer of 0 or 1.

2. The polypeptide of claim 1, wherein Y is amino acid residues at positions 158 to 162 of SEQ ID NO:

14, amino acid residues at positions 153 to 162 of SEQ ID NO;

14, amino acid residues at positions 143 to 162 of SEQ ID NO;

14, amino acid residues at positions 133 to 162 of SEQ ID NO;

14, or amino acid residues at positions 99 to 162 of SEQ ID NO;

14.

3. The polypeptide according to claim 1, wherein p is 0 (zero).

4. The polypeptide according to claim 1, wherein the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, SEQ ID NO;

3, SEQ ID NO;

4, SEQ ID NO;

5 and SEQ ID NO;

6, SEQ ID NO;

26 and SEQ ID NO;

27.

5. The polypeptide according to claim 1, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:

18, SEQ ID NO;

19, SEQ ID NO;

20, SEQ ID NO;

21, SEQ ID NO;

22 and SEQ ID NO;

23, SEQ ID NO;

28 and SEQ ID NO;

29.

6. The polypeptide according to claim 5, wherein the polypeptide has the amino acid sequence of SEQ ID NO:

18.

7. The polypeptide according to claim 5, wherein the polypeptide has the amino acid sequence of SEQ ID NO:

22.

8. The polypeptide according to claim 5, wherein the polypeptide has the amino acid sequence of SEQ ID NO:

23.

9. A chimeric polypeptide comprising the polypeptide of claim 1 and a biologically active molecule, wherein the biologically active molecule is fused at the N-terminus or the C-terminus of the polypeptide, and wherein said biologically active molecule shows an increased circulating half-life compared to the circulating half-life of the non-fused form of said biologically active molecule.

10. The chimeric polypeptide of claim 9, wherein the biologically active molecule is a hormone, cytokine, growth factor, co-stimulatory molecule, hormone receptor, cytokine receptor, growth factor receptor, or short peptide.

11. The chimeric polypeptide according to claim 9, wherein said biologically active molecule is EPO.

12. The chimeric polypeptide according to claim 9, wherein said biologically active molecule is p40 (SEQ ID NO:

17) or, TNF receptor.

13. The chimeric polypeptide according to claim 12, wherein said biologically active molecule is a variant of said p40 in which the variant consists of Asn303Gln substitution in the said p40.

14. The chimeric polypeptide according to claim 9, wherein said biologically active molecule is a G-CSF.

15. The chimeric polypeptide according to claim 9, wherein said biologically active molecule is a GM-CSF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, human growth hormone, bone morphogenetic protein-1, interferon-alpha, IL-10, FSH, Factor VII, CTLA4, IFN-beta, PD-1, IL-10R, CXCL-11, TGF-beta receptor, TGF-beta, IL-17R, GLP-1, BTC, OPG, RANK.

16. The chimeric polypeptide according to claim 9, wherein said biologically active molecule is a secreted protein.

17. The chimeric polypeptide according to claim 16, wherein said biologically active molecule is a mature form of the secreted protein.

18. The chimeric polypeptide according to claim 9, wherein said biologically active molecule is a Fab region of an antibody.

19. The chimeric polypeptide according to claim 9, wherein said polypeptide and said biologically active molecule are coupled to each other via a linker, wherein the linker is an albumin linker or a synthetic linker.

20. The chimeric polypeptide of claim 19, wherein said albumin linker comprises amino acid sequence 321 to 323, 318 to 325, 316 to 328, 313 to 330, 311 to 333, or 306 to 338 of SEQ ID NO:

25.

21. The chimeric polypeptide of claim 19, wherein said synthetic linker is a peptide of 10 to 20 amino acid residues, wherein the peptide being composed of Gly and Ser residues.

22. A method of producing the polypeptide according to claim 1 or claim 9, wherein the method comprises the steps of:

(i) introducing a nucleic acid molecule coding for the polypeptide into a mammalian host cell, (ii) growing the cell under conditions where the polypeptide can be expressed in its growth medium; and

(iii) harvesting the expressed polypeptide.

23. An isolated nucleic acid molecule which encodes the polypeptide of claim 1 or the chimeric polypeptide according to claim 9.

24. The nucleic acid molecule according to claim 23, wherein said polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:

18, SEQ ID NO;

19, SEQ ID NO;

20, SEQ ID NO;

21, SEQ ID NO;

22, SEQ ID NO;

23, SEQ ID NO;

28 and SEQ ID NO;

29.

25. The nucleic acid molecule according to claim 24, wherein the nucleic acid molecule is one selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, SEQ ID NO;

3, SEQ ID NO;

4, SEQ ID NO;

5, SEQ ID NO;

6, SEQ ID NO;

26 and SEQ ID NO;

27.

26. An expression vector comprising the nucleic acid molecule according to claim 23.